For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

Semaglutide: origin, structure and research history

Research Library › Incretin & Amylin

Semaglutide is a synthetic analogue of the human hormone glucagon-like peptide-1 (GLP-1), carrying two amino-acid substitutions and a fatty-acid side chain designed to bind the blood protein albumin. It was developed by Novo Nordisk, whose chemists published its discovery in 2015, and the FDA first approved it in 2017 as Ozempic for type 2 diabetes. As of October 2026 it is the active ingredient of several FDA-approved Novo Nordisk products, while compounded and “research use” versions are not FDA-approved.

Key facts

TypeSynthetic, acylated GLP-1 analogue (peptide); molecular formula C187H291N45O59
Developed byNovo Nordisk A/S, Denmark
First describedDiscovery paper published in the Journal of Medicinal Chemistry in 2015
Designed targetGLP-1 receptor; 94% sequence homology to human GLP-1
Approved brands (US)Ozempic (2017), Rybelsus (2019), Wegovy (2021), Wegovy pill (2025)
Regulatory status (Oct 2026)FDA-approved in branded Novo Nordisk products; shortage resolved Feb 2025; FDA proposed in April 2026 to exclude it from the 503B bulks list; unapproved and "research use" versions subject to FDA warnings

Who developed it

Semaglutide was created by a research team at Novo Nordisk in Denmark. The group described its design in a 2015 paper in the Journal of Medicinal Chemistry, building on the company’s earlier work on liraglutide, an earlier GLP-1 analogue [1].

Novo Nordisk remains the sponsor of every FDA-approved semaglutide product [2, 5].

Structure and design

Semaglutide is based on the sequence of human GLP-1, a hormone released from the intestine. According to its discovery paper, it differs from the native hormone by two amino-acid substitutions, at positions 8 and 34, and it carries a side chain attached at lysine 26 [1]. The position 8 change was made to stabilize the molecule against enzymatic breakdown [2].

The side chain combines a linker with an 18-carbon fatty diacid. The developers reported that this fatty acid portion and its linking chemistry were the key features in their goal of creating a longer-acting analogue designed to bind serum albumin [1]. The FDA label lists 94% sequence homology to human GLP-1 and a molecular weight of about 4,114 g/mol [2].

Research history

  • 2015: Novo Nordisk chemists publish the discovery of semaglutide [1]
  • December 2017: FDA approves Ozempic for type 2 diabetes [2, 3]
  • September 2019: FDA approves Rybelsus, a second semaglutide product, for type 2 diabetes [4]
  • June 2021: FDA approves Wegovy for chronic weight management [5]
  • December 2025: FDA approves the Wegovy pill for weight management [6]
  • March 2026: FDA approves a higher-dose Wegovy product under its National Priority Voucher pilot [7]

Regulatory status as of October 2026

Semaglutide is FDA-approved only as the active ingredient of Novo Nordisk’s branded products. Semaglutide injection was on the FDA drug shortage list for a period; the FDA declared that shortage resolved on 21 February 2025, and its temporary enforcement flexibility for compounders ended in April 2025 for state-licensed pharmacies and in May 2025 for outsourcing facilities [8].

On 30 April 2026 the FDA proposed excluding semaglutide, along with tirzepatide and liraglutide, from the 503B bulks list, which governs what outsourcing facilities may compound from bulk ingredients. The comment period closed on 29 June 2026 [11]; no final determination had been announced as of October 2026.

The FDA has stated that compounded semaglutide is not reviewed for safety, effectiveness or quality, that the salt forms semaglutide sodium and semaglutide acetate are different active ingredients from the approved drug, and that it has warned companies selling semaglutide labeled “for research purposes” or “not for human consumption” [9]. In 2025 it created a “green list” import alert for GLP-1 active ingredients [12], and in March 2026 it issued 30 warning letters to telehealth firms over claims about compounded GLP-1 products [10].

About this reference page

Kalibra Labs does not currently supply Semaglutide. This page is published as a neutral scientific and regulatory reference. Browse the Incretin & Amylin guide or the FDA Peptide Regulatory Tracker.

Frequently asked questions

Who developed semaglutide?

Semaglutide was developed by Novo Nordisk in Denmark; its discovery was published in 2015 [1].

When was semaglutide first approved?

The FDA approved semaglutide in December 2017 as Ozempic for type 2 diabetes [2, 3].

Is compounded semaglutide FDA-approved?

No. The FDA states that compounded semaglutide does not undergo agency review for safety, effectiveness or quality, and that salt forms such as semaglutide sodium are different active ingredients from the approved drug [9].

How does semaglutide differ from natural GLP-1?

It has two amino-acid substitutions and a fatty-acid side chain at lysine 26, changes its developers designed to resist enzymatic breakdown and to bind albumin [1, 2].

Can semaglutide still be compounded in 2026?

The shortage that allowed wider compounding ended in 2025, and in April 2026 the FDA proposed excluding semaglutide from the 503B bulks list; a final decision was pending as of October 2026 [8, 11].

Sources

  1. Lau J, Bloch P, Schäffer L, et al., Kruse T. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380. doi:10.1021/acs.jmedchem.5b00726. Link
  2. Novo Nordisk. OZEMPIC (semaglutide) injection, prescribing information (Initial U.S. approval 2017; sections 11 and 12.1). Drugs@FDA, NDA 209637. Link
  3. Novo Nordisk. Novo Nordisk receives FDA approval of OZEMPIC (semaglutide) injection for the treatment of adults with type 2 diabetes. Press release, 5 Dec 2017. Link
  4. U.S. FDA. FDA approves first oral GLP-1 treatment for type 2 diabetes. Press announcement, 20 Sep 2019. Link
  5. Novo Nordisk. WEGOVY (semaglutide) injection, prescribing information, revised 06/2021. Drugs@FDA, NDA 215256. Link
  6. Novo Nordisk A/S. Wegovy pill approved in the US as first oral GLP-1 for weight management. Company announcement, 22 Dec 2025. Link
  7. U.S. FDA. FDA approves fourth product under National Priority Voucher program, higher dose semaglutide. Press announcement, 19 Mar 2026. Link
  8. U.S. FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated through 1 Apr 2026). Link
  9. U.S. FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated 1 Oct 2026). Link
  10. U.S. FDA. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. Press announcement, 3 Mar 2026. Link
  11. U.S. FDA. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. Press announcement, 30 Apr 2026. Link
  12. U.S. FDA. FDA launches green list to protect Americans from illegal imported GLP-1 drug ingredients. Press announcement, 5 Sep 2025. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top